Drug-induced tinnitus and other hearing disorders

Drug Safety

Volumn 14, Issue 3, 1996, Pages 198-212

  Seligmann, Hannah ^a   Podoshin, Ludwig ^a,b   Ben David, Jacob ^a,b   Fradis, Milo ^a,b   Goldsher, Moshe ^a  

^a BNAI ZION MEDICAL CENTER   (Israel)

^b TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE; AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; ANTIINFLAMMATORY AGENT; ANTIMALARIAL AGENT; ANTINEOPLASTIC AGENT; BUMETANIDE; CHLOROQUINE; CISPLATIN; DIURETIC AGENT; EAR DROPS; ERYTHROMYCIN; ETACRYNIC ACID; FUROSEMIDE; LOCAL ANESTHETIC AGENT; MACROLIDE; NONSTEROID ANTIINFLAMMATORY AGENT; QUININE; SALICYLIC ACID DERIVATIVE; TETRACYCLINE DERIVATIVE; TORASEMIDE; VANCOMYCIN;

COCHLEA; DRUG BLOOD LEVEL; HEARING; HEARING DISORDER; HEARING LOSS; HUMAN; INNER EAR; KIDNEY FUNCTION; OTOTOXICITY; PATIENT MONITORING; PRIORITY JOURNAL; REVIEW; TINNITUS; VESTIBULOCOCHLEAR NERVE;

EID: 0029960117     PISSN: 01145916     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002018-199614030-00006     Document Type: Review

References (135)

1. Lien EJ, Lipsett LR, Lien LL. Structure side effect sorting of drugs: VI. Ototoxicities. J Clin Hosp Pharm 1983; 8: 15-33
2. Koegel Jr L. Ototoxicity: a contemporary review of aminoglycosides, loop diuretics, acetylsalicylic acid, quinine, erythromycin, and cisplatinum. Am J Otol 1985; 6: 190-9
3. Rybak LP. Drug ototoxicity. Annu Rev Pharmacol Toxicol 1986; 26: 79-99
4. Boston Collaborative Drug Surveillance Program. Drug-induced deafness. JAMA 1973; 224: 515-6
5. Lien EJ. Side effects and drug design. New York: Marcel Dekker, 1987
6. Brummett RE, Griest SE, Mulkey M, et al. Specific etiologies of tinnitus. In: Shulman A, Aran JM, Tondorf J, et al., editors. Tinnitus: diagnosis and treatment. Philadelphia: Lea and Febiger, 1991: 391-8
7. Norris CH. Drugs affecting the inner ear. Drugs 1988; 36: 754-72
8. Huang MY, Schacht J. Drug-induced ototoxicity: pathogenesis and prevention. Med Toxicol Adverse Drug Exp 1989; 4: 452-67
9. Matz GJ. Clinical perspectives on ototoxic drugs. Ann Otol Rhinol Laryngol 1990; 99: 39-41
10. Brummett RE, Fox KE. Aminoglycoside-induced hearing loss in humans. Antimicrob Agents Chemother 1989; 33: 797-800
11. Brummett RE, Morrison RB. The incidence of aminoglycoside antibiotic-induced hearing loss. Arch Otolaryngol Head Neck Surg 1990; 116: 406-10
12. Lesar TS. Drug-induced ear and eye toxicity. In: Di Piro JT, Talbert RL, Hayes PE, et al., editors. Pharmacotherapy. 2nd ed., chap 82. Norwalk (CN): Appleton & Lange, 1993
13. De Jong TPVM, Donckerwolcke RAMG, Boemers TM. Neomycin toxicity in bladder irrigation. J Urol 1993; 150: 1199-202
14. Johnson CA. Hearing loss following the application of topical neomycin. J Burn Care Rehabil 1988; 9: 162-4
15. Thomas J, Marion MS, Hinojosa R. Neomycin ototoxicity. Am J Otolaryngol 1992; 13: 54-5
16. Govaerts PJ, Claes J, Van De Heyning PH, et al. Aminoglycoside-induced ototoxicity. Toxicol Lett 1990; 52: 227-51
17. Bergstrom L, Thompson PL. Ototoxicity. In: Northern JL, editor. Hearing disorders, 2nd ed. Boston: Little, Brown & Co., 1984: 241-54
18. Bendush CL. Ototoxicity: clinical toxicity and comparative information. In: Whelton A, Neu H, editors. The aminoglycosides: microbiology, clinical use and toxicology. New York: Marcel Dekker, 1982: 153-7
19. Griffin JP. Drug-induced ototoxicity. Br J Audiol 1988; 22: 195-210
20. Takada A, Bledsoe S, Schacht J. An energy-dependent step in aminoglycoside ototoxicity: prevention of gentamycin ototoxicity during reduced endolymphatic potential. Hear Res 1985; 19: 245-51
21. Dulon D, Zajic G, Aran JM, et al. Aminoglycoside antibiotics impair calcium entry but not viability and motility of cochlear outer hair cells. J Neurosci Res 1989; 24: 338-46
22. Huang MY, Schact J. Formation of a cytotoxic metabolite from gentamycin by liver. Biochem Pharmacol 1990; 40: R11-4
23. Crann SA, Huang MY, McLaren JD, et al. Formation of a toxic metabolite from gentamycin by a hepatic cytosolic fraction. Biochem Pharmacol 1992; 43: 1835-9
24. Schact J. Biochemical basis of aminoglycoside ototoxicity. Otolaryngol Clin North Am 1993; 26: 845-56
25. Garetz SL, Rhee DJ, Schact J. Sulfhydryl compounds and antioxidants inhibit cytotoxicity to outer hair cells of a gentamicin metabolite in vitro. Hear Res 1994; 77: 75-80
26. Garetz SL, Rhee DJ, Schact J. Attenuation of gentamicin by glutathione [abstract]. 15th Annual Meeting, Association for Research in Otolaryngology; 1993; 16: 141
27. Garetz SL, Altschuler RA, Schact J. Attenuation of gentamicin ototoxicity by glutathione in the guinea pig in vivo. Hear Res 1994; 77: 81-7
28. Higashi K. Unique inheritance of streptomicin-induced deafness. Clin Genet 1989; 35: 433-6
29. Hu DN, Qiu WQ, Wu BT, et al. Genetic aspects of antibiotic-induced deafness: mitochondrial inheritance. J Med Genet 1991; 28: 79-83
30. Prezant TR, Agapian JV, Bohlman MC, et al. Mitochondrial ribosomal RNA mutation associated with both antibiotic-induced and non-syndromic deafness. Nature Genet 1993; 4: 289-94
31. Hutchin T, Haworth I, Higashi K, et al. A molecular basis for human hypersensitivity to aminoglycoside antibiotics. Nucleic Acids Res 1993; 21: 4174-9
32. Cortopassi G, Hutchin T. A molecular and cellular hypothesis for aminoglycoside-induced deafness. Hear Res 1994; 78: 27-30
33. Black FO, Pesznecker SC. Vestibular ototoxicity: clinical considerations. Otolaryngol Clin North Am 1993; 26: 713-36
34. Moore RD, Smith CR, Lietman PS. Risk factors for the development of auditory toxicity in patients receiving aminoglycosides. J Infect Dis 1984; 149: 23-30
35. Haydon RC, Thelin JW, Davis WE. Erythromycin ototoxicity: analysis and conclusions based on 22 case reports. Otolaryngol Head Neck Surg 1984; 92: 678-84
36. Schweitzer VG, Olson NR. Ototoxic effect of erythromycin therapy. Arch Otolaryngol 1984; 110: 258-60
37. Dantzenberg B, Piperno D, Diot P, et al. Clarithromycin in the treatment of Mycobacterium avium lung infections in patients with AIDS: Clarithromycin Study Group of France. Chest 1995; 107: 1035-40
38. Cramer R. Erythromycin ototoxicity. Drug Intell Clin Pharm 1986; 20: 764-5
39. Swanson DJ, Sung RJ, Fine MJ, et al. Erythromycin ototoxicity: prospective assessment with serum concentrations and audiograms in a study of patients with pneumonia. Am J Med 1992; 92: 61-8
40. Brummett RE. Ototoxic liability of erythromycin and analogues. Otolaryngol Clin North Am 1993; 26: 811-9
41. Sacristán JA, Soto J. Erythromycin ototoxicity: methodology and conclusions [letter]. Am J Med 1993; 94: 227-8
42. Kanfer A, Stamatakis G, Torlotin C, et al. Changes in erythromycin pharmacokinetics induced by renal failure. Clin Nephrol 1987; 29: 147-50
43. Brittain DC. Erythromycin. Med Clin North Am 1987; 71: 1147-54
44. Swanson DJ, Derry CL Fine MJ, et al. Erythromycin pharmacokinetics associated with ototoxic effects in patients. Pharmacotherapy 1990; 10: 232-6
45. Moral A, Navasa M, Rimola A, et al. Erythromycin ototoxicity in liver transplant patients. Transpl Int 1994; 7: 62-4
46. Brummett RE, Fox KE. Vancomycin- and erythromycin-induced hearing loss in humans. Antimicrob Agents Chemother 1989; 33: 791-6
47. Brummett RE, Morrison R, Matthews J. Possible site of action of erythromycin ototoxicity in the human [abstract]. 11th Annual Meeting. Association for Research in Otolaryngology; 1989
48. Wallace MR, Miller LK, Nguyen M-T. Ototoxicity with azithromycin. Lancet 1994; 343: 241-3
49. Farber BF, Moellering RC. Retrospective study of the preparations of vancomycin from 1974-1981. Antimicrob Agents Chemother 1987; 23: 138-41
50. Bailie GR, Neal D. Vancomycin ototoxicity and nephrotoxicity: a review. Med Toxicol Adverse Drug Exp 1988; 3: 376-86
51. Hermans PE, Wilheim MP. Vancomycin. Mayo Clin Proc 1987; 62: 901-5
52. Brummett RE. Ototoxicity of vancomycin and analogues. Otolaryngol Clin North Am 1993; 26: 821-8
53. Lutz H, Lenarz T, Weidauer H, et al. Ototoxicity of vancomycin: an experimental study in guinea pigs. ORL J Otorhinolaryngol Relat Spec 1991; 53: 273-8
54. Goodey RJ. Drugs in the treatment of tinnitus. In: Kitaha M, editor. Tinnitus: pathophysiology and management. Tokyo: Igaku-Shoin, 1988: 64-73
55. Shulman A. Medical methods, drug therapy, and tinnitus control strategies. In: Shulman A, Aran JM, Tondorf J, et al., editors. Tinnitus: diagnosis and treatment. Philadelphia: Lea and Febiger, 1991: 453-89
56. Drew TM, Altman R, Black K, et al. Minocycline for prophylaxis of infection in Neisseria meningitidis: high rate of side effects in recipients. J Infect Dis 1976; 133: 194-8
57. Gump GW, Ashikaga T, Fink T, et al. Side effects of minocycline: different dosage regimens. Antimicrob Agents Chemother 1977; 12: 642-6
58. Giles CL, Soble AR. Intracranial hypertension and tetracycline therapy. Am J Ophthalmol 1971; 72: 981-2
59. Ohlrich GD, Ohlrich JG. Papilloedema in an adolescent due to tetracycline. Med J Aust 1977; 1: 334-5
60. Walters BNJ, Gubbay SS. Tetracycline and benign intracranial hypertension: report of five cases. BMJ 1981; 282: 19-20
61. Davis DM. Drug-induced deafness. Adverse Drug React Bull 1978; 69: 244-77
62. Drucker T. Drugs that can cause tinnitus. ATA Newslett 1979; 4: 3-5
63. Brummett RE. Drug-induced ototoxicity. Drugs 1980; 19: 412-28
64. Miller JJ. Handbook of ototoxicity. Boca Raton (FL): CRC Press, 1980
65. Dukes MNG, Aronson JK, editors. Meyler's side effects of drugs. 11th ed. Amsterdam: Elsevier. 1990: 651-9
66. Miwa T, Tsukamura M, Kawase Y, et al. Adverse reactions of enviomycin during treatment for pulmonary tuberculosis. Tuberculosis 1980; 55: 201-6
67. Gorman SE, Dela Cruz F, Paloucek F. Ketoconazole and zidovudine overdose: case report and review. Vet Hum Toxicol 1992; 34: 332
68. Costa I, Castanet J, Lacour JP, et al. Vertigo and hypokalaemia: two rare adverse effects of itraconazole. Therapie 1994; 49: 149
69. Davanipour Z, Stewart CE, McGann DG. Hepatitis B vaccination and asymmetric tinnitus and hearing loss [abstract]. Clin Res 1994; 42: 341A
70. Stewart BJA, Umesh Prabhu P. Reports of sensorineural deafness after measles, mumps, and rubella immunisation. Arch Dis Child 1993; 69: 153-5
71. Hulbert TV, Larsen RA, Davis CL, et al. Bilateral hearing loss after measles and rubella vaccination in an adult [letter]. N Engl J Med 1991; 325: 134
72. Kanda Y, Shigeno K, Kinoshita N, et al. Sudden hearing loss associated with interferon. Lancet 1994; 343: 1134-5
73. Walker EM, Fazekas-May MA, Bowen WR. Nephrotoxic and ototoxic agents. Clin Lab Med 1990; 10: 323-54
74. Day RO, Graham GG, Bieri D, et al. Concentration-response relationships for salicylate-induced ototoxicity in normal volunteers. Br J Clin Pharmacol 1989; 28: 695-702
75. Brien J. Ototoxicity associated with salicylates. Drug Saf 1993; 9: 143-8
76. Temple AR. Acute and chronic effects of aspirin toxicity and their treatment. Arch Intern Med 1981; 141: 364-9
77. Miller RR, Jick H. Acute toxicity of aspirin in hospitalized medical patients. Am J Med Sci 1977; 274: 271-9
78. Hawkins J, Johnson L, Preston R. Cochlear microvasculature in normal and damaged ear. Laryngoscope 1971; 82: 1091-4
79. Malotte M, Jung TTK, Miller SK, et al. Effect of nonsteroidal anti-inflammatory drugs on cochlear blood flow. Otolaryngol Head Neck Surg 1990; 103: 187-9
80. Jung T, Juhn S. Prostaglandins in the perilymph. 7th Midwinter Research Meeting, Association for Research in Otolaryngology; 1984: 107-8
81. Kawata R, Urade Y, Tachibana M, et al. Prostaglandin synthesis by the cochlea. Prostaglandins 1988; 35: 173-84
82. Cazals Y, Li X, Aurousseau C, et al. Acute effects of noradrenaline-related vasoactive agents on the ototoxicity of aspirin. Hear Res 1988; 36: 89-96
83. Jung T, Miller S, Mowery G, et al. Effect of leukotriene inhibitor (L-663536) on metabolites in salicylate ototoxicity. 14th Mid-winter Research Meeting. Association for Research in Otolaryngology; 1991: 73-4
84. Jung T, Park Y, Miller S, et al. Effects of exogenous arachidonic acid metabolites applied on round window membrane on hearing, and their levels in the perilymph. Acta Otolaryngol 1992; Suppl. 493: 171-6
85. Ishii T, Bernstein JM, Balogh Jr K. Distribution of tritium-labelled salicylate in the cochlea: an autoradiographical study. Ann Otol Rhinol Laryngol 1967; 76: 368-76
86. Silverstein H, Bernstein JM, Davis DG. Salicylate toxicity: a biochemical and electrophysiological study. Ann Otol Rhinol Laryngol 1967; 76: 118-28
87. Krzanowski Jr JJ, Matschinsky FM. A phosphocreatine gradient opposite to that of glycogen in the organ of Corti and the effect of salicylate on adenosine triphosphate and P-creatine in cochlear structures. J Histochem Cytochem 1971; 19: 321-4
88. McCabe PA, Dey DL. The effect of aspirin upon auditory sensitivity. Ann Otol Rhinol Laryngol 1965; 74: 312-25
89. McFadden D. Tinnitus: facts, theories and treatments. Washington, DC: National Academy Press, 1982
90. Lindgren F, Axellson A. Temporary threshold shift induced by noise exposure and moderate salicylate intake. Scand Audiol 1987; 16: 41-4
91. Günther T, Rebentisch E, Vormann J. Enhanced ototoxicity of salicylate by magnesium deficiency. Magnes Bull 1989; 11: 15-8
92. Günther T, Rebentisch E, Vormann J. Protection against salicylate ototoxicity by zinc. J Trace Elem Electrolytes Health Dis 1989; 3: 51-3
93. Fratianni T, Jung TTK, Miller SK, et al. Effect of adrenergic blockers on sodium salicylate-induced ototoxicity. Otolaryngol Head Neck Surg 1990; 103: 233-6
94. Pinals RS, Frank S. Relative efficiency of indomethacin and acetylsalicylic acid in rheumatoid arthritis. N Engl J Med 1967; 276: 512-4
95. Lynch S, Brogden RN. Etodolac: a preliminary review of its pharmacodynamic activity and therapeutic use. Drugs 1986; 31: 288-300
96. Wasner C, Britton MC, Kraines G, et al. Nonsteroidal anti-inflammatory agents in rheumatoid arthritis and ankylosing spondylitis. JAMA 1981; 246: 2168-72
97. Chapman P. Naproxen and sudden hearing loss. J Laryngol Otol 1982; 96: 163-6
98. Morris DL, Fletcher A. Hyperacusis after treatment with mefenamic acid. BMJ 1986; 293: 823
99. Clissold SP, Beresfold R. Proquazone: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficiency in rheumatic diseases and pain states. Drugs 1987; 33: 478-502
100. Gallagher KL, Jones JR. Furosemide-induced ototoxicity. Ann Intern Med 1979; 91: 744-5
101. Rybak LP. Ototoxicity of loop diuretics. Otolaryngol Clin North Am 1993; 26: 829-44
102. Hommerich CP. Ototoxicity of loop diuretics: morphological and electrophysiological examinations in animal experiments. Adv Otorhinolaryngol 1990; 44: 92-164
103. Wells TG. The pharmacology and therapeutics of diuretics in the pediatric patient. Pediatr Clin North Am 1990; 37: 463-504
104. Wigand ME, Heidland A. Ototoxic side effects of high doses of furosemide in patients with uremia. Postgrad Med J 1971; 47 Suppl.: 54-6
105. Kshirsager N, Dohanukar SA, Shah BP. Furosemide pharmacokinetics and its relevance to ototoxicity. J Postgrad Med 1978; 24: 20-3
106. Ng PSY, Conley CE, Ing TS. Deafness after ethacrynic acid. Lancet 1969; i: 673-4
107. Melichar I, Syka J. The effects of ethacrynic acid upon the potassium concentration in guinea pig cochlear fluids. Hear Res 1978; 1: 35-41
108. Koch T, Gloddek B. Inhibition of adenylate cyclase-coupled G protein complex by ototoxic diuretics and cis-platinum in the inner ear of guinea pigs. Eur Arch Otorhinolaryngol 1991; 248: 459-64
109. Rybak LP, Whitwoch C, Scott V. Organic acids do not alter the cochlear effects of ethacrynic acid. Hear Res 1990; 46: 95-100
110. Tuzel IH. Comparison of adverse reactions to bumetanide and furosemide. J Clin Pharmacol 1981; 21: 615-9
111. Keefe PE. Ototoxicity from oral furosemide. Drug Intell Clin Pharm 1978; 12: 428-30
112. Heidland A, Wigand ME. Hearing loss induced by the use of high doses of furosemide in the treatment of uremia [in German]. Klin Wochenschr 1970; 48: 1052-6
113. Rybak LP, Morizono T. Effect of furosemide upon endolymph potassium concentration. Hear Res 1982; 7: 223-31
114. Dunn CJ, Fitton A, Brogden RN. Torasemide: an update of its pharmacological properties and therapeutic efficacy. Drugs 1995; 49: 121-42
115. Toone EC. Ototoxicity of chloroquine. Arthritis Rheum 1965; 8: 475-6
116. Dwivedi GS, Mehra YN. Ototoxicity of chloroquine phosphate. J Laryngol Otol 1978; 92: 701-3
117. Miller JJ. CRC handbook of ototoxicity. Boca Raton (FL): CRC Press, 1985
118. Schonwald S, Shannon M. Unsuspected quinine intoxication presenting as acute deafness and mutism. Am J Emerg Med 1991; 9: 318-20
119. Manku MS, Horrobin DF. Chloroquine, quinine, procaine, quinidine, tricyclic anti-depressants, and methylxanthines as prostaglandin agonists and antagonists. Lancet 1976; ii: 1115-7
120. Smith DI, Lawrence M, Hawkins JE. Effects of noise and quinine on the vessels of the stria vascularis: an image analysis study. Am J Otolaryngol 1985; 6: 280-9
121. Short SO, Kaplari JN. Changes in cochlear blood flow and hearing with acute quinine toxicity. Otolaryngol Head Neck Surg 1983; 91: 100-3
122. Moss RA. Drug-induced immune thrombocytopenia. Am J Hematol 1980; 9: 439-46
123. Jung TT, Rhee CK, Lee CS, et al. Ototoxicity of salicylate, nonsteroidal anti-inflammatory drugs and quinine. Otolaryngol Clin North Am 1993; 26: 791-810
124. Puel J-L, Bobbin RP, Fallon M. Salicylate, mefenamate, meclofenamate, and quinine on cochlear potentials. Otolaryngol Head Neck Surg 1990; 102: 66-73
125. Dukes MNG, Aronson JK, editors. Meyler's side effects of drugs. 11th ed. Amsterdam: Elsevier, 1990: 581-602
126. Moroso MJ, Blair R. A review of cisplatin ototoxicity. J Otolaryngol 1983; 12: 365-9
127. Schweitzer VG. Ototoxicity of chemotherapeutic agents. Otolaryngol Clin North Am 1993; 26: 759-89
128. Pasic TR, Dobie RA. cis-Platinum ototoxicity in children. Laryngoscope 1991; 101: 985-91
129. Vermorken J. Ototoxicity of ris-diamminedichloroplatinum: influence of dose schedule and mode of administration. Eur J Cancer Clin Oncol 1983; 19: 53-8
130. Schaeffer SD, Wright FG, Post JD. Cisplatin vestibular toxicity. Cancer 1981; 47: 857-9
131. McAlpine D. The ototoxic mechanism of cisplatin. Hear Res 1990; 47: 191-204
132. Myers S. The 'platinum effect' of cis-platinum-induced hearing loss. Otolaryngol Head Neck Surg 1991; 104: 122-7
133. Blakley BW, Gupta AK, Myers SF, et al. Risk factors for ototoxicity due to cisplatin. Arch Otolaryngol Head Neck Surg 1994; 120: 541-6
134. Plinkert PK, Krober S. Early detection of cisplatin-induced ototoxicity using evoked otoacoustic emissions [in German]. Laryngorhinootologie 1991; 70: 457-62
135. Schweitzer VG, Dolan DF, Davidson T. Amelioration of cisplatin-induced ototoxicity by fosfomycin. Laryngoscope 1986; 96: 948-58